Fukuda M, et al. - Researchers assessed 5,130 patients to quantify the effectiveness and tolerability of sitagliptin in older candidates with type 2 diabetes mellitus. At week 52, they observed a significant decrease in glycated hemoglobin (−0.7 ± 1.1%) and glycoalbumin levels (−2.2 ± 3.8%). No change in the percentage of patients with hypoglycemia was noticed from the baseline (3.3%) to week 52 (2.8%) of sitagliptin administration. They reported that an escalation in sitagliptin dose for combination therapy with antidiabetic drug(s) increased the percentage of subjects with hypoglycemia. Hence, they suggested the cautious utilization of sitagliptin.